Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 38 Breast Neoplasms 31 Lung Neoplasms 25 Colorectal Neoplasms 15 Prostatic Neoplasms 13 Pancreatic Neoplasms 11 Ovarian Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Head and Neck Neoplasms 9 Sarcoma 8 Colonic Neoplasms 8 Carcinoma, Hepatocellular 8 Uterine Cervical Neoplasms 7 Glioma 7 Esophageal Neoplasms 7 Melanoma 6 Lymphoma 6 Endometrial Neoplasms 6 Neoplastic Cells, Circulating 5 Multiple Myeloma 5 Brain Neoplasms 5 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Neoplasm, Residual 4 Gastrointestinal Neoplasms 4 Carcinoma, Squamous Cell 4 Carcinoma, Renal Cell 4 Adenocarcinoma 4 Thrombosis 3 Rectal Neoplasms 3

Interventions

Trastuzumab 8 pyrotinib 6 pertuzumab 4 Docetaxel 3 Capecitabine 3 tucatinib 2 Paclitaxel 2 Neoadjuvant Therapy 2 trastuzumab deruxtecan 1 neratinib 1 inavolisib 1 Taxoids 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Genetic Testing 1 Drug Therapy 1 Carboplatin 1 Blood Specimen Collection 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HER2-positive Breast Cancer × Blood Specimen Collection × Clear all

NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡